NCT07508254Not yet recruitingPhase 4
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Triple (Atorvastatin, Ezetimibe, and Bempedoic Acid) Versus Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment. The main questions it aims to answer are: * Does triple therapy result in greater reduction in LDL-C compared to dual therapy? * What adverse effects occur in participants receiving triple therapy? Researchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels. Participants will: * Receive either dual or triple lipid-lowering therapy for 3 months * Attend regular follow-up visits for clinical assessment and laboratory testing * Undergo lipid profile evaluation at baseline and at the end of the study
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 27 Mar 2026
- Start date
- 1 May 2026
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Punjab Institute of Cardology
- NCT number
- NCT07508254
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 May 2026 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Intolerance or hypersensitivity to study drugs.
Lab values
- Liver or ALT/AST greater than three times the upper normal.
- Renal dysfunction: estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m².
Other
- Gout with frequent bouts or severe hyperuricemia.
- Pregnancy/lactation
Who the study is looking for
- Must be older than 18 years, male or female.
- Diagnosis of ACS (Acute Coronary Syndrome) is confirmed when hospitalized.
- Eligible for high-intensity statin therapy (atorvastatin)
- Patients can provide written informed consent.
- Patients will be eager to cooperate with study drugs and follow-up visits.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Punjab Institute of Cardiology Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.